Management of non-alcoholic steatohepatitis (NASH): a multiorgan disease driven by insulin resistance, obesity and T2D
Sign in to receive more information about videos like this
As the 28th European congress on Obesity draws near, Prof Cusi, USA explains a paradigm shift and why drugs that have had an impact for CV disease also have a significant potential in the management of NASH. Amongst them, PPARs may have a role to play in addition to management of obesity and lifestyle interventions.
This content is restricted to site members. If you are an existing user, please log in. New users may register below.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.